Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20562481 | 0.87 | POLB (0.53) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16294051 | 0.86 | KDM4E (0.53) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL154368 | 0.83 | HSD17B10 (0.68) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30873972 | 0.82 | SLC13A5 (0.62) | FFAR4POLBHSD17B10NPSR1 | |
| SCHEMBL491188 | 0.82 | HSD17B10 (0.71) | MEN1KMT2APOLBHSD17B10 | |
| SCHEMBL1209727 | 0.82 | SLC13A5 (0.62) | FFAR4POLBHSD17B10NPSR1 | |
| SCHEMBL30436820 | 0.82 | HSD17B10 (0.71) | MEN1KMT2APOLBHSD17B10 | |
| SCHEMBL7694108 | 0.82 | MEN1 (0.51) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4083314 | 0.81 | KDM4E (0.53) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16307003 | 0.81 | LTB4R (0.57) | KDM4EMEN1KMT2ASMN1; SMN2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041837-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11666557-B2 | Triazolone compounds and uses thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20200138790-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2020-05-07 | — | — | US | disclosed |
| US-10568871-B2 | Triazolone compounds and uses thereof | TEMPEST THERAPEUTICS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-2935228-B9 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2 INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170239223-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2017-08-24 | — | — | US | disclosed |
| EP-2935228-B1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2 INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9676754-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2935228-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | Inception 2, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014201073-A9 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2014201073-A9 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150080412-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2822931-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | Inception 2, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| WO-2014201073-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014201073-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014099503-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2013134562-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| WO-2001053298-A1 | IMIDAZOPYRIDINES AND RELATED AZACYCLIC DERIVATIVES AS SELECTIVE MODULATORS OF BRADYKININ B2 RECEPTORS | NEUROGEN CORPORATION (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666557-B2 | Triazolone compounds and uses thereof | PPARA, PPARG, PPARD | KDM4E 2133/4885ALDH1A1 589/4885MEN1 3885/4885 |
| US-20240041837-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | KDM4E 2133/4885ALDH1A1 589/4885MEN1 3885/4885 |
| US-10568871-B2 | Triazolone compounds and uses thereof | PPARA, PPARG, PPARD | KDM4E 2133/4885ALDH1A1 589/4885MEN1 3885/4885 |
| US-20200138790-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | KDM4E 2133/4885ALDH1A1 589/4885MEN1 3885/4885 |
| US-20150080412-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | KDM4E 2341/4885ALDH1A1 673/4885MEN1 3492/4885 |
| US-20170239223-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | KDM4E 2133/4885ALDH1A1 589/4885MEN1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.